Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors

Trial Profile

Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Talazoparib (Primary) ; Irinotecan; Temozolomide
  • Indications Cancer metastases; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 1 Apr 2018 to 30 Jun 2019.
    • 12 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 30 Jun 2018.
    • 18 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top